enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. List of drugs granted breakthrough therapy designation

   en.wikipedia.org/wiki/List_of_drugs_granted...

   Treatment of people aged twelve years of age and older with solid tumors that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy [2]

3. Multiple myeloma - Wikipedia

   en.wikipedia.org/wiki/Multiple_myeloma

   A 2016 study concluded that stem cell transplant is the preferred treatment for multiple myeloma. [107] There are two types of stem cell transplants to treat multiple myeloma. [108] In autologous hematopoietic stem-cell transplantation (ASCT) – the patient's stem cells are collected from the patient's blood. The patient is given high-dose ...

4. Cancer breakthrough as groundbreaking trials see seriously ...

   www.aol.com/groundbreaking-cancer-trials-see...

   Ms Ross began her treatment for myeloma in November last year and in just seven months went into complete remission. She has only experienced fairly minor side effects of the new drug, such as ...

5. Multiple Myeloma Research Consortium - Wikipedia

   en.wikipedia.org/wiki/Multiple_Myeloma_Research...

   The mission of the Multiple Myeloma Research Consortium (MMRC) is to champion collaboration with and integration across academia and industry and to focus on speed and innovation to bring the most promising multiple myeloma treatments to patients faster.

6. Elranatamab - Wikipedia

   en.wikipedia.org/wiki/Elranatamab

   Elranatamab, sold under the brand name Elrexfio, is a medication used for the treatment of multiple myeloma. [8] [12] Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. [8] [12] [13] [14] Elranatamab is given by subcutaneous injection. [8] [12]

7. Teclistamab - Wikipedia

   en.wikipedia.org/wiki/Teclistamab

   Teclistamab, sold under the brand name Tecvayli, is a human bispecific monoclonal antibody used for the treatment of relapsed and refractory multiple myeloma. [8] It is a bispecific antibody that targets the CD3 receptor expressed on the surface of T-cells and B-cell maturation antigen (), which is expressed on the surface of malignant multiple myeloma B-lineage cells.